DGAP-News

Sangui BioTech International Inc.: Revenues slightly improved in the first half of the 2014 financial year

DGAP-News: Sangui BioTech International Inc. / Key word(s): Half Year
Results
Sangui BioTech International Inc.: Revenues slightly improved in the
first half of the 2014 financial year

14.02.2014 / 13:30

---------------------------------------------------------------------

Sangui BioTech: Revenues slightly improved in the first half of the 2014
financial year

Research and development for new patent application, preparation of animal
test continued

Witten, Germany, February 14, 2014

For the first half (as of December 31, 2013) of its 2014 financial year
Sangui BioTech International, Inc. reports revenues from product sales and
royalties in the amount of USD60,303 an increase of 25.5% over the revenues
in the first half of the financial year 2013. In the second quarter
(October through December 2013) revenues amounted to USD33,776 an
improvement of 27.3% as compared with the most recent quarter(July through
September 2013).

Research and development expenses amounted to USD107,234 (H1/2013: USD
23,950). The increase is due to the preparations made for filing a new
patent application as well as of animal testing aimed at demonstrating the
functionality of Sangui's technology with respect to various indications.
The net loss attributable to shareholders of the parent company came to
USD570,032 (H1/2013: USD665,579), the cash outflow from operations during
the six months amounted to USD337,416 (H1/2013: USD266,507).

As of December 31, 2013, the equity ratio was 59.2% (June 30, 2013: 56.7%).

In the course of the second quarter the shareholders of SastoMed GmbH
resolved to swap the shareholder loans outstanding for equity preserving
their respective share in the stock of the company. The resulting
obligation to invest another EUR200,000 was fulfilled during the quarter.
SanguiBioTech GmbH holds 25% in SastoMed GmbH, Sangui has granted SastoMed
the global distribution rights for the wound therapeutic Granulox.

Sangui BioTech International, Inc. ('SGBI') is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges.
Its purpose is to provide financing and access to the capital markets for
the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.

For more information please contact:

Joachim Fleing
Phone: [phone]
Fax: [phone]
e-mail: [e-mail]


End of financial news

---------------------------------------------------------------------

14.02.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


252695 14.02.2014